scholarly journals Recommendations on the use of MF59-adjuvanted trivalent influenza vaccine (Fluad®): Supplemental statement of seasonal influenza vaccine for 2011-2012

2011 ◽  
Vol 37 (ACS-6) ◽  
pp. 1-68
Author(s):  
Keyword(s):  
Influenza Vaccine ◽  
Seasonal Influenza ◽  
Seasonal Influenza Vaccine ◽  
Trivalent Influenza Vaccine

scholarly journals Safety and immunogenicity profiles of an adjuvanted seasonal influenza vaccine in Guatemalan children

2014 ◽  
Vol 8 (09) ◽  
pp. 1160-1168 ◽  
Author(s):  
Adib Rodriguez Solares ◽  
Carlos Grazioso Aragon ◽  
Rodolfo Urruela Pivaral ◽  
David Prado-Cohrs ◽  
Victor Sales-Carmona ◽  
...  
Keyword(s):  
Adverse Events ◽  
Influenza Vaccine ◽  
Seasonal Influenza ◽  
Vaccine Dose ◽  
Antibody Responses ◽  
Entire Study ◽  
Seasonal Influenza Vaccine ◽  
Adjuvanted Vaccine ◽  
Trivalent Influenza Vaccine ◽  
Antibody Titers

Introduction: The efficacy of non-adjuvanted seasonal influenza vaccine in young children is considered to be suboptimal.  This study compared the safety and immunogenicity profiles of MF59-adjuvanted, trivalent, influenza vaccine (ATIV) and non-adjuvanted, trivalent, influenza vaccine (TIV) in Guatemalan children (N = 360) between 6 and < 60 months of age. Methodology: Children received two doses of ATIV or TIV administered four weeks apart. Solicited adverse reactions were recorded for seven days after each vaccination. Serious adverse events were recorded throughout the entire study period. Antibody responses were assessed by hemagglutination inhibition (HI) assay at baseline, four weeks after administration of the first vaccine dose, and three weeks after administration of the second dose. Results: Both ATIV and TIV were well tolerated, with similar rates of solicited reactions and adverse events observed in response to both vaccines. MF59-adjuvanted vaccine induced considerably higher antibody titers than did TIV. After two doses, the B strain-specific antibody response to TIV was insufficient to meet the Center for Biologics Evaluation and Research (CBER) licensure criterion for seroprotection, whereas responses to the MF59-adjuvanted vaccine met the seroprotection criterion against all three strains. Cross-reactive antibody responses to MF59-adjuvanted vaccine met the CBER seroprotection criterion against all three strains after two doses; B strain-specific heterologous responses to non-adjuvanted TIV were inadequate. Conclusions: The MF59-adjuvanted seasonal influenza vaccine was well-tolerated and highly immunogenic in children 6 to < 60 months of age, inducing seroprotective antibody titers against both the vaccine strains and antigenically distinct heterologous strains.

scholarly journals Healthcare Workers’ Perspectives on the Upcoming COVID-19 Vaccine in Terms of Their Exposure to the Influenza Vaccine in Riyadh, Saudi Arabia: A Cross-Sectional Study

Vaccines ◽  
2021 ◽  
Vol 9 (5) ◽  
pp. 465
Author(s):  
Leena R. Baghdadi ◽  
Shatha G. Alghaihb ◽  
Alanoud A. Abuhaimed ◽  
Dania M. Alkelabi ◽  
Rawan S. Alqahtani
Keyword(s):  
Saudi Arabia ◽  
Influenza Vaccine ◽  
Work Experience ◽  
Healthcare Workers ◽  
Seasonal Influenza ◽  
Cross Sectional Study ◽  
Sectional Study ◽  
Cross Sectional ◽  
Seasonal Influenza Vaccine ◽  
History Of

In 2019, a novel severe acute respiratory syndrome (SARS-CoV-2 (COVID-19)) caused a global pandemic. There was an urgent need to develop a vaccine against COVID-19 to reduce its spread and economic burden. The main objective of this study was to understand the attitudes and concerns of healthcare workers (HCWs) towards the upcoming COVID-19 vaccine, whether their decision was influenced by their history of taking the seasonal influenza vaccine, and factors that influence the acceptance of the upcoming COVID-19 vaccine. This was a cross-sectional study conducted in Riyadh, Saudi Arabia. We selected and surveyed 356 HCWs via an electronic self-administered questionnaire. A total of 61.16% of HCWs were willing to receive the COVID-19 vaccine, and 55.9% of them had received the seasonal influenza vaccine in the preceding year (2019–2020). The strongest predictors for taking the COVID-19 vaccine were the HCWs’ belief that the COVID-19 vaccine would be safe, needed even for healthy people, that all HCWs should be vaccinated against COVID-19, and that HCWs will have time to take the vaccine. Being female, being middle aged, having <5 years of work experience, having no fear of injections, and being a non-smoker were predictive factors for taking the upcoming COVID-19 vaccine. No associations were found between the intention to take the COVID-19 vaccine and a history of taking the seasonal influenza vaccine.

scholarly journals Mapping the inequality of the global distribution of seasonal influenza vaccine

2021 ◽  
pp. 0308518X2199835
Author(s):  
Yen Ching Yau ◽  
Michael T Gastner
Keyword(s):  
Influenza Vaccine ◽  
Respiratory Diseases ◽  
Seasonal Influenza ◽  
Developed Countries ◽  
Essential Medicines ◽  
World Health ◽  
Equitable Access ◽  
Seasonal Influenza Vaccine ◽  
Choropleth Map ◽  
Vaccine Distribution

With an estimated annual worldwide death toll of between 290 000 and 650 000, seasonal influenza remains one of the deadliest respiratory diseases. Influenza vaccines provide moderate to high protection and have been on the World Health Organization’s Model List of Essential Medicines since 1979. Approximately 490 million doses of influenza vaccine are produced per year, but an investigation of geographic allocation reveals enormous disparities. Here, we present two maps that visualise the inequality of the distribution across 195 countries: a conventional choropleth map and a cartogram. In combination, these two maps highlight the widespread lack of coverage in Africa and many parts of Asia. As COVID-19 vaccines are now being distributed in developed countries, data for seasonal influenza vaccine distribution emphasises the need for policymakers to ensure equitable access to COVID-19 vaccines.

Uptake and Beliefs Regarding Seasonal Influenza Vaccination Among Childcare Center Staff, Administrators, and Parents

2016 ◽  
Vol 38 (3) ◽  
pp. 367-370 ◽  
Author(s):  
Terri Rebmann ◽  
Travis M. Loux ◽  
Brendan Daly
Keyword(s):  
Influenza Vaccine ◽  
Seasonal Influenza ◽  
Response Rate ◽  
Vaccine Uptake ◽  
Agency Staff ◽  
Seasonal Influenza Vaccine ◽  
Center Staff ◽  
Perceived Seriousness ◽  
Logistic Regressions ◽  
Childcare Center

Surveys were distributed to parents and childcare agency staff to determine seasonal influenza vaccine uptake. Multivariate logistic regressions identified vaccination determinants. Overall, 351 parents and staff participated (response rate, 32%). One-half (168 [48%]) received vaccine. Vaccination predictors included healthcare provider or employer recommendation, perceived seriousness, and no vaccine fear.Infect Control Hosp Epidemiol 2017;38:367–370

scholarly journals Clinical effectiveness of seasonal influenza vaccine among adult cancer patients

Cancer ◽  
2013 ◽  
Vol 119 (22) ◽  
pp. 4028-4035 ◽  
Author(s):  
Inbal Vinograd ◽  
Noa Eliakim-Raz ◽  
Laura Farbman ◽  
Rina Baslo ◽  
Ahmed Taha ◽  
...  
Keyword(s):  
Influenza Vaccine ◽  
Cancer Patients ◽  
Seasonal Influenza ◽  
Clinical Effectiveness ◽  
Seasonal Influenza Vaccine
Sign in / Sign up

Export Citation Format

Share Document